Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Trials identified included in the qualitative analysis
| Study, year | Setting | No of pts | Tumor histotype | ECT protocol |
|---|---|---|---|---|
| Rotunno, 201537 | Two-center, Italy | 55 | non-melanoma SC | ESOPE |
| Cabula, 201538 | Multi-center, Italy | 125 | BC | ESOPE |
| Mozzillo, 201539 | Single-center, Italy | 15 | melanoma | ESOPE |
| Landstrom, 201540 | Single-center, Sweden | 19 | HNSCC | Other Intratumoral BLM injection (1000 IU/cm3 and tumor electroporation by means of six 1100 V/cm square wave pulses with 0.1 ms duration |
| Granata, 201541 | Single-center, Italy | 13 | pancreatic cancer | ESOPE |
| Kreuter, 201542 | Multi-center, Germany | 56 | various | ESOPE |
| Quaglino, 201543 | Multi-center, Europe | 121 | various | ESOPE |
| Mir-Bonafé, 201544 | Single-center, Spain | 31 | melanoma | ESOPE |
| Campana, 201445 | Single-center, Italy | 39 | HNSCC | ESOPE |
| Ricotti, 201446 | Single-center, Italy | 30 | melanoma | ESOPE |
| Campana, 201447 | Single-center, Italy | 55 | BC | ESOPE |
| Edhemovic, 201429 | Single-center, Slovenia | 16 | CRC-liver mts | ESOPE In this trial, the ESOPE protocol was integrated by the application of variable geometry electrodes for the treatment of deep visceral metastases. |
| Seccia, 201448 | Single-center, Italy | 9 | HNSCC | ESOPE |
| Campana, 201450 | Two-center, Italy | 34 | STS | ESOPE |
| Solari, 201451 | Single-center, Italy | 39 | various | ESOPE |
| Di Monta, 201452 | Single-center, Italy | 19 | KS | ESOPE |
| Caracò, 201349 | Single-center, Italy | 60 | melanoma | ESOPE |
| Perrone, 201353 | Single-center, Italy | 9 | V-SCC | ESOPE |
| Benevento, 201254 | Single-center, Italy | 12 | BC | ESOPE |
| Mevio, 201255 | Single-center, Italy | 15 | HNSCC | ESOPE |
| Campana, 201220 | Single-center, Italy | 35 | BC | ESOPE |
| Latini, 201256 | Single-center, Italy | 18 | KS | ESOPE |
| Matthiessen, 201257 | Single-center, Denmark | 12 | BC | ESOPE |
| Gargiulo, 201258 | Single-center, Italy | 52 | non-melanoma SC | ESOPE |
| Campana, 201221 | Single-center, Italy | 85 | melanoma | ESOPE |
| Curatolo, 201259 | Two-center, Italy | 23 | KS | ESOPE |
| Kis, 201160 | Single-center, Hungary | 9 | melanoma | ESOPE |
| Matthiessen, 201122 | Two-center, Denmark-UK | 52 | various | ESOPE |
| Skarlatos I, 201161 | Multi-center, Greece | 52 | various | ESOPE |
| Campana, 200962 | Single-center, Italy | 52 | various | ESOPE |
| Quaglino, 200863 | Single-center, Italy | 14 | melanoma | ESOPE |
| Larkin, 200764 | Single-center, Ireland | 30 | various | ESOPE |
| Gaudy, 200665 | Single-center, France | 12 | melanoma | Other Intratumoral BLM injection (concentration, 4 mg/mL; dose, 1 mg/cm3 of tumor volume was followed, after 10 minutes, by the application of electric pulses (six 100 μsec-long pulses, 4 pulses/sec, electric field >600V/cm |
Manuscript quality criteria
| Manuscript quality criteria | |||
|---|---|---|---|
| Trial design | Description of Patient population | Treatment delivery and outcome assessment | Analysis of results and interpretation |
| 1. Prospective trial | 1. Setting (curative / palliative) | 1. Type of anaesthesia | 1. Summary of trial endpoints |
| 2. Trial registration | 2. Drug route and dosages | ||
| 3. Comparative trial | 2. Demographic data (in tabular form) | 3. Pulse generator | 2. Predictive factors |
| 4. Mention of trial design | 4. EP parameters | ||
| 5. Multicenter study | 3. No of tumors | 5. Electrode description | 3. Other patient outcome parameters |
| 6. Mention of sponsor | 6. Tumor safety margins indicated | ||
| 7. Trail hypothesis and sample size | 4. Tumor location | 7. Deviation from SOPs | 4. Results interpretation |
| 8. Informed consent | 5. Tumor histotype | 9. Criteria for retreatment | 5. Comparison to historical controls |
| 9. EC approval | 8. Tumor coverage with EP | ||
| 10. Structured abstract | 10. Total No of ECT sessions | ||
| 11. Rationale of the trial | 6. Tumor size | 11. ECT sessions required a Number of electrochemotherapy (ECT) sessions required for achieving response (either complete or partial) on baseline tumors | 6. Future directions |
| 12. A priori inclusion criteria | 12. Toxicity criteria | ||
| 13. Follow-up dates | 7. Visceral mts indicated | 13. Response criteria | 7. COI statement |
| 14. Statistical methods | 14. Evaluation of tumor control | ||
| 15. Software used | 8. Concomitant treatments | 15. ECT success b Decision rule for determining ECT success | |
| 16. C.I., p-values | 16. Keep track of patients lost to follow-up | ||